MiRNA Scientific es una empresa de atención médica de precisión comprometida a mejorar la salud pública transformando el manejo del cáncer a nivel mundial. La plataforma patentada de gestión de enfermedades miR® de la empresa se desarrolló para revolucionar el estándar de atención basada en valores para los cánceres e inicialmente se centra en los cánceres urológicos MiRNA Scientific is a precision healthcare company committed to improving public health by transforming cancer management globally. The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers
La prueba inicial proporcionada por miR Disease Management Platform® es la prueba de cáncer de próstata miR Sentinel™, la primera y única prueba de orina con biopsia líquida no invasiva que detecta, clasifica y puede monitorear con precisión el cáncer de próstata a nivel molecular.
.png)
The miR Sentinel™ Prostate Cancer Test can transform cancer management by delivering accurate and actionable results to providers and patients from a single urine sample, answering the two most important questions:
IS THERE EVIDENCE OF PROSTATE CANCER?
IF SO, HOW SEVERE IS THE RISK OF AGGRESSIVE DISEASE?
This result indicates that the patient presents No Molecular Evidence of Prostate Cancer
This result indicates that the patient presents Molecular Evidence of Elevated Risk for Aggressive Prostate Cancer
This result indicates that the patient presents Molecular Evidence of Low-Risk for Aggressive Prostate Cancer
The prostate naturally releases molecules into urine, including several different kinds of RNA genetic material that vary depending on the absence or presence and severity of prostate cancer. This information obtained from the urine sample is all MiRNA Scientific needs to accurately detect and classify cancer using the miR Sentinel Prostate Cancer Test – it is not reliant on clinical risk factors such as PSA, DRE or biopsy material
The miR Sentinel™ Prostate Cancer Test requires a single, contact-free urine specimen, with no related risk of side effects
miR Sentinel Prostate Cancer Test can replace an array of multiple blood tests, invasive biopsies and imaging procedures with one comprehensive solution.
Unlike biopsies, MRIs and other current options, the miR Disease Management Platform® is high-throughput and can be easily administered for large volumes of patients.
Prostate cancer is prevalent and deadly.
It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.
Our non-invasive, pain-free miR Sentinel™ Prostate Cancer Test can help healthcare providers, patients, and employers realize true cost-effectiveness and efficiency in prostate cancer detection and management.
Help identify patients with the greatest need by adding miR Sentinel™ Prostate Cancer Test to your detection and classification toolbox.
Experience a non-invasive, accurate, easily-accessible prostate cancer test that delivers helpful results to your provider with a single urine specimen.
Keep your employees and their families healthy and reduce excessive urologic cancer screening, treatment costs and unproductive workdays with a straightforward and highly accessible urine test.
Our molecular diagnostic capabilities are a novel approach to cancer detection and classification, using advanced sncRNA interrogation techniques and a proprietary scoring algorithm.
miR’s technology isolates pre-classified, informative RNA entities from urinary exosomes, and uses proprietary tools to detect and process signals from numerous RNA entities that are evident in the specimens.
The miR Sentinel™ Prostate Cancer Test is healthcare’s first and only urine test that detects and classifies prostate cancers with a high level of accuracy—no rectal exam, blood test, biopsy or strict urine requirements.
miR Sentinel provides the most comprehensive non-invasive prostate cancer risk assessment test.
.png)